Low-Grade Gliomas in Patients with Noonan Syndrome: Case-Based Review of the Literature.
Mariachiara LodiLuigi BoccutoAndrea CaraiAntonella CacchioneEvelina MieleGiovanna Stefania ColafatiFrancesca Diomedi-CamasseiLuca De PalmaAlessandro De BenedictisElisabetta FerrettiGiuseppina CatanzaroAgnese PòAlessandro De LucaMartina RinelliFrancesca Romana LepriEmanuele AgoliniMarco TartagliaFranco LocatelliAngela MastronuzziPublished in: Diagnostics (Basel, Switzerland) (2020)
Noonan syndrome (NS) is a congenital autosomic dominant condition characterized by a variable spectrum from a clinical and genetical point of view. Germline mutations in more than ten genes involved in RAS-MAPK signal pathway have been demonstrated to cause the disease. An higher risk for leukemia and solid malignancies, including brain tumors, is related to NS. A review of the published literature concerning low grade gliomas (LGGs) in NS is presented. We described also a 13-year-old girl with NS associated with a recurrent mutation in PTPN11, who developed three different types of brain tumors, i.e., an optic pathway glioma, a glioneuronal neoplasm of the left temporal lobe and a cerebellar pilocytic astrocytoma. Molecular characterization of the glioneuronal tumor allowed to detect high levels of phosphorylated MTOR (pMTOR); therefore, a therapeutic approach based on an mTOR inhibitor (everolimus) was elected. The treatment was well tolerated and proved to be effective, leading to a stabilization of the tumor, which was surgical removed. The positive outcome of the present case suggests considering this approach for patients with RASopathies and brain tumors with hyperactivated MTOR signaling.